AASLD 2016: The Liver Meeting – Lucinda K. Porter, RN
Abstract # 57 Poor Adherence to Hepatocellular Carcinoma (HCC) Surveillance in a U.S. Cohort of 2376 Patients with Chronic Hepatitis C (CHC) and Cirrhosis – Sally A. Tran, et al.
Abstract #1768 Identifying Barriers to Hepatocellular Carcinoma Surveillance in a National Sample of Patients With Cirrhosis – David S. Goldberg, et al.
Abstract #1762 Lack of Compliance to Hepatocellular Carcinoma (HCC) Screening Guidelines in Hepatitis B (HBV) or C (HCV) Virus Co-Infected HIV Patients with Cirrhosis – Sophie Willemse (Netherlands)
The incidence of liver cancer is rising. Several studies looked at how effective the medical profession is doing at screening for hepatocellular carcinoma (HCC).
Conclusion: These three large studies (two in the U.S. and one in the Netherlands) concluded that surveillance is poor.
Editorial Comments: If you have cirrhosis or hepatitis B (with/without cirrhosis), talk to your doctor about HCC screening recommendations. In the U.S., screening includes imaging (ultrasound, CT, or MRI) every 6 months.
Lucinda K. Porter, RN, is a long-time contributor to the HCV Advocate and author of “Free from Hepatitis C” and “Hepatitis C One Step at a Time.” She blogs at www.LucindaPorterRN.com and HepMag.com
Read the entire HCV Advocate newsletter